News & Updates

Baricitinib delays, lowers frequency of flares in JIA
Baricitinib delays, lowers frequency of flares in JIA
23 Jun 2022 byRoshini Claire Anthony

In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.

Baricitinib delays, lowers frequency of flares in JIA
23 Jun 2022
NAFLD linked to heightened type 2 diabetes risk
NAFLD linked to heightened type 2 diabetes risk
22 Jun 2022

Children with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of type 2 diabetes, a study reports. Other risk factors for T2D include severity of liver histology, body mass index, and female sex.

NAFLD linked to heightened type 2 diabetes risk
22 Jun 2022
Normal weight obesity in adolescents tied to cardiometabolic risk
Normal weight obesity in adolescents tied to cardiometabolic risk
21 Jun 2022

Adolescents with normal weight obesity (NMO) may present with several cardiometabolic risk factors, putting them at greater risk of developing vascular events or diabetes, suggests a recent study.

Normal weight obesity in adolescents tied to cardiometabolic risk
21 Jun 2022
Insulin resistance tied to atherogenic lipoprotein/lipid, cIMT in obese youths
Insulin resistance tied to atherogenic lipoprotein/lipid, cIMT in obese youths
20 Jun 2022

Insulin resistance in young people with obesity is positively associated with an atherogenic lipoprotein/lipid profile and carotid intima-media thickness (cIMT), regardless of their glucose tolerance status, suggests a study.

Insulin resistance tied to atherogenic lipoprotein/lipid, cIMT in obese youths
20 Jun 2022
Dulaglutide: A new horizon for T2D treatment in kids
Dulaglutide: A new horizon for T2D treatment in kids
18 Jun 2022